1
Sarah S Bacus: Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy. Becton Dickinson and Company, David W Highet, May 7, 1996: US05514554 (73 worldwide citation)

A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24 ...


2
Sarah S Bacus: Method for prognosticating response to cancer therapy. Becton Dickinson and Company, Robert M Hallenbeck, February 22, 1994: US05288477 (58 worldwide citation)

A method for prognosticating the effectiveness of a chemotherapy using monoclonal antibodies and ligand molecules. The putative anti-cancer agent has binding specificity for a oncogenic receptor molecule on the membrane of a cancer cell, such as HER-2/neu. When the putative agent binds to the oncoge ...


3
James W Bacus, Sarah S Bacus: Method and apparatus for determining the amount of oncogene protein product in a cell sample. Cell Analysis Systems, Fitch Even Tabin & Flannery, October 12, 1993: US05252487 (45 worldwide citation)

An apparatus and method for determining an amount of oncogene protein product copies in a cell includes an optical conversion module for measuring an amount of optically enhanced DNA in a cell sample. A subsystem for measuring an amount of an optically enhanced oncogene protein product protein produ ...


4
Sarah S Bacus: Method and quantification assay for determining c-kit/SCF/pAKT status. Ventana Medical Systems, McDonnell Boehnen Hulbert & Berghoff, September 2, 2008: US07419777 (22 worldwide citation)

This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.


5
Sarah S Bacus: Method for quantitating a protein by image analysis. Ventana Medical Systems, McDonnell Boehnen Hulbert & Berghoff, November 8, 2005: US06962789 (16 worldwide citation)

The present invention provides a method for determining expression levels of one or a multiplicity of target proteins in a tissue or cell sample.


6

7
Sarah S Bacus, Jason Hill: Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor. Targeted Molecular Diagnostics, K&L Gates, January 4, 2011: US07862995 (1 worldwide citation)

The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinic ...


8
Sarah S Bacus: Method for determining the response to cancer therapy. Ventana Medical Systems, McDonnell Boehnen Hulbert & Berghoff, November 16, 2010: US07833698

The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.


9
Sarah S Bacus: Method and quantification assay for determining c-kit/SCF/pAKT status. Ventana Medical Systems, Ventana Medical Systems, April 18, 2017: US09625446

This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.


10
Sarah S Bacus: Methods for predicting cardiac toxicity. Quintiles Transnational Corporation, K&L Gates, April 29, 2014: US08709738

Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for de ...